Pelacarsen
Highest phase reached
Phase 3
Drug type
Oligonucleotide
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Oligonucleotide
- Drug name
- Pelacarsen
- akcea apo a lrx
- AKCEA-APO(a)-LRx
- all p ambo 5 o 6 5 tris 3 6 2 acetamido 2 deoxy beta d galactopyranosyloxy hexylamino 3 oxopropoxymethyl methyl amino 5 oxopentanamido hexoxy phospho 2 o 2 methoxyethyl 5 methyl p thiouridylyl 3 o 5 o 2 o 2 methoxyethyl guanylyl 3 o 5 o 2 o 2 methoxyethyl 5 methylcytidylyl 3 o 5 o 2 o 2 methoxyethyl 5 methyluridylyl 3 o 5 o 2 o 2 methoxyethyl 5 methylcytidylyl 3 o 5 o 2 deoxy 5 methyl p thiocytidylyl 3 o 5 o 2 deoxy p thioguanylyl 3 o 5 o p thiothymidylyl 3 o 5 o p thiothymidylyl 3 o 5 o 2 deoxy p thioguanylyl 3 o 5 o 2 deoxy p thioguanylyl 3 o 5 o p thiothymidylyl 3 o 5 o 2 deoxy p thioguanylyl 3 o 5 o 2 deoxy 5 methyl p thiocytidylyl 3 o 5 o p thiothymidylyl 3 o 5 o 2 o 2 methoxyethyl 5 methyluridylyl 3 o 5 o 2 o 2 methoxyethyl guanylyl 3 o 5 o 2 o 2 methoxyethyl 5 methyl p thiouridylyl 3 o 5 o 2 o 2 methoxyethyl 5 methyl p thiouridylyl 3 o 5 o 2 o 2 methoxyethyl 5 methylcytidine
- ALL-P-AMBO-5-O-(((6-(5-((TRIS(3-(6-(2-ACETAMIDO-2-DEOXY-.BETA.-D-GALACTOPYRANOSYLOXY)HEXYLAMINO)-3-OXOPROPOXYMETHYL))METHYL)AMINO-5-OXOPENTANAMIDO)HEXOXY))PHOSPHO)-2-O-(2-METHOXYETHYL)-5-METHYL-P-THIOURIDYLYL-(3-O->5-O)-2-O-(2-METHOXYETHYL)GUANYLYL-(3-O->5-O)-2-O-(2-METHOXYETHYL)-5-METHYLCYTIDYLYL-(3-O->5-O)-2-O-(2-METHOXYETHYL)-5-METHYLURIDYLYL-(3-O->5-O)-2-O-(2-METHOXYETHYL)-5-METHYLCYTIDYLYL-(3-O->5-O)-2-DEOXY-5-METHYL-P-THIOCYTIDYLYL-(3-O->5-O)-2-DEOXY-P-THIOGUANYLYL-(3-O->5-O)-P-THIOTHYMIDYLYL-(3-O->5-O)-P-THIOTHYMIDYLYL-(3-O->5-O)-2-DEOXY-P-THIOGUANYLYL-(3-O->5-O)-2-DEOXY-P-THIOGUANYLYL-(3-O->5-O)-P-THIOTHYMIDYLYL-(3-O->5-O)-2-DEOXY-P-THIOGUANYLYL-(3-O->5-O)-2-DEOXY-5-METHYL-P-THIOCYTIDYLYL-(3-O->5-O)-P-THIOTHYMIDYLYL-(3-O->5-O)-2-O-(2-METHOXYETHYL)-5-METHYLURIDYLYL-(3-O->5-O)-2-O-(2-METHOXYETHYL)GUANYLYL-(3-O->5-O)-2-O-(2-METHOXYETHYL)-5-METHYL-P-THIOURIDYLYL-(3-O->5-O)-2-O-(2-METHOXYETHYL)-5-METHYL-P-THIOURIDYLYL-(3-O->5-O)-2-O-(2-METHOXYETHYL)-5-METHYLCYTIDINE
- ionis apo a lrx
- Ionis-apo(a)-lrx
- isis 681257
- ISIS 681257
- isis 681257 free acid
- isis 681257 galnac3 conjugated aso targeting human lipoprotein a free acid
- ISIS-681257 (GALNAC3--CONJUGATED ASO TARGETING HUMAN LIPOPROTEIN (A)) FREE ACID
- ISIS-681257 FREE ACID
- pelacarsen
- Pelacarsen
- Pelacarsen (TQJ230) 80 mg s.c.
- pelacarsen [INN]
- PELACARSEN [USAN]
- Pelacarsen [WHO-DD]
- pelacarsen inn
- pelacarsen tqj230 80 mg s c
- pelacarsen usan
- pelacarsen who dd
- CAS registry numbers
- 1637637-70-7
- ChEMBL ID
- CHEMBL4298202
- FDA ingredient codes (UNII)
- LSO9H7UZ90
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- pelacarsen
- Type
- Nucleic acid
- Drug name stem
- -rsen
- Mechanism
- LPA mRNA antisense inhibitor
- Action type
- ANTISENSE_INHIBITOR
- Target
- LPA mRNA
- Protein identifier
- ENSG00000198670
- Mechanism
- LPA mRNA antisense inhibitor
- Action type
- Inhibitor
- Target
- LPA mRNA
- Protein identifier
- ENSG00000198670
Open Targets mechanisms
- Mechanism
- LPA mRNA antisense inhibitor
- Action type
- ANTISENSE INHIBITOR
- Target
- LPA mRNA
- Condition
- Cardiovascular Diseases
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000319
- Subject identifier
- D002318
- Condition
- Liver Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001421
- Subject identifier
- D008107
- Condition
- Coronary Artery Disease
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001645
- Subject identifier
- D003324
- Condition
- Kidney Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003086
- Subject identifier
- D007674
- Condition
- Aortic Valve Stenosis
- Highest recorded phase
- 2
- Condition identifier
- HP:0001650
- Subject identifier
- D001024
- Condition
- Hyperlipoproteinemias
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0037748
- Subject identifier
- D006951
- Condition identifier
- EFO_0000319
- Highest recorded phase
- 3
- Condition identifier
- EFO_0001421
- Highest recorded phase
- 1
- Condition identifier
- EFO_0001645
- Condition identifier
- EFO_0003086
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004995
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005010
- Condition identifier
- MONDO_0005068
- Condition identifier
- MONDO_0037748
- Highest recorded phase
- 3
- NCT03070782
- NCT03392051
- NCT03426033
- NCT03506854
- NCT05026996
- NCT05305664
- NCT05900141
- NCT05646381
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Sequences
- Component
- Sequence
- Type
- Nucleic Acid
- Sequence
- (3'-5') R1-U=G-C-U-C-d(C=G=T=T=G=G=T=G=C=T=)U-G-U=U=C
Related records
Trials (16)
- A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
- A Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pelacarsen (ISIS 681257) in Healthy Japanese Participants
- An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
- An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
- Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Clopidogrel
- Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Warfarin
- Influence of Pelacarsen on Patients After Myocardial Infarction With High Lp(a) Values (PEMILA)
- Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL
- Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
- Managed Access Programs for TQJ230, Pelacarsen
- Pelacarsen Roll-over Extension Program
- Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS APO(a)-LRx in Healthy Volunteers With Elevated Lipoprotein(a)
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS-APO(a)Rx in Participants With High Lipoprotein(a)
- Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy Patients
- Study to Assess the Pharmacokinetics of Pelacarsen (TQJ230) in Participants With Mild Hepatic Impairment Compared to Matched Healthy Participants
In development for (6)
- Aortic valve stenosis Phase 2
- Cardiovascular disorder Phase 2
- Coronary artery disorder Phase 1
- Hyperlipoproteinemia Phase 3
- Kidney disorder Phase 1
- Liver disorder Phase 1
Other linked conditions (1)
Targets (1)
- LPA LPA mRNA antisense inhibitor